Superworth

Attovia Therapeutics ATTO

Biotechnology, Healthcare
$15.05
−0.92%
Market cap
$687.1M
PE
n/m
one or more of the four quarters through 2026-06-30 missing
Forward PE
n/m
not a meaningful number
Price to sales
n/m
one or more of the four quarters through 2026-06-30 missing
EV/EBIT
n/m
not a meaningful number
Revenue, 12 months
n/m
one or more of the four quarters through 2026-06-30 missing
Net margin
n/m
one or more of the four quarters through 2026-06-30 missing
Free cash flow yield
n/m
not a meaningful number

Charts

Financials

Income statement for ATTO, by quarter
Income statementQ1 FY25Q2 FY25Q1 FY26Q2 FY26
$0$0$0$450K
R&D$11.9M$13.6M$16.7M$18.9M
SG&A$4.2M$3M$3.2M$3.3M
−$16.1M−$16.6M−$20M−$21.8M
Net income−$15.2M−$14.4M−$18.7M−$20.7M
−$4.05−$3.71−$4.49−$4.88
3.8M3.9M4.2M4.2M

Revenue: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

R&D: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

SG&A: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Operating income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Net income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

EPS, diluted: Q1 FY25 and Q1 FY26: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY25 and Q1 FY26: share-days: the 6-month average less the second quarter's.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Biotechnology nearest Attovia Therapeutics' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
ATTOAttovia Therapeutics$687.1Mn/mn/an/mn/mn/m
MGTXMeiraGTx$895.1M13.1×15.4×2.3×n/m19.9%
VCELVericel$2.1B88.1×157×6.8×+23%7.9%
PLXProtalix BioTherapeutics$206.3M11.1×33.6×2.6×+30%23.5%
ADMAAdma Biologics$2.5B15.8×21.3×4.8×+8%33.0%
Peer median$1.5B14.5×27.5×3.7×+23%21.7%

More on Attovia Therapeutics

Each number over time

Its groups

About

Industry
Biotechnology
Sector
Healthcare

Valuation data, not investment advice. Prices as of .